Chapter
The Power and Limits of Reputation in FDA Regulation
4:02:27 - 4:06:31 (04:03)
This podcast episode discusses how the FDA's reputation as a regulator is also a constraint to its power in the pharmaceutical industry, and how the motives of those running regulatory agencies may affect their actions.
Clips
The podcast explores the history of the FDA's regulation of pharmaceuticals, including how the agency's reputation for competence and vigilance has contributed to its power and how it has resisted efforts to curb its authority.
4:02:27 - 4:05:04 (02:36)
Summary
The podcast explores the history of the FDA's regulation of pharmaceuticals, including how the agency's reputation for competence and vigilance has contributed to its power and how it has resisted efforts to curb its authority. It also highlights the drawbacks of lengthy approval timelines for drugs or vaccines, including increased costs and decreased ability to iterate on the product.
ChapterThe Power and Limits of Reputation in FDA Regulation
Episode#331 – Balaji Srinivasan: How to Fix Government, Twitter, Science, and the FDA
PodcastLex Fridman Podcast
Chomsky's idea that people believe what they believe and regulate accordingly is reflected in the ambitions of regulatory agencies and company CEOs.
4:05:04 - 4:06:31 (01:27)
Summary
Chomsky's idea that people believe what they believe and regulate accordingly is reflected in the ambitions of regulatory agencies and company CEOs. Despite their constructed narratives of doing good, the motives of regulatory agencies and CEOs may be driven by the desire to expand their power or make money.